Free Trial
OTCMKTS:ANTH

Anthera Pharmaceuticals (ANTH) Stock Price, News & Analysis

Anthera Pharmaceuticals logo

About Anthera Pharmaceuticals Stock (OTCMKTS:ANTH)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
23,585 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.

Remove Ads
Receive ANTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anthera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ANTH Stock News Headlines

MACK - Merrimack Pharmaceuticals, Inc.
Musk’s real agenda in D.C.
In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of America…
See More Headlines

ANTH Stock Analysis - Frequently Asked Questions

Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTH) announced its quarterly earnings results on Monday, March, 5th. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.09.

Shares of Anthera Pharmaceuticals reverse split on Monday, May 1st 2017. The 1-8 reverse split was announced on Friday, April 28th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

Shares of ANTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Anthera Pharmaceuticals investors own include Ocular Therapeutix (OCUL), Novavax (NVAX), Arena Pharmaceuticals (ARNA), Bristol-Myers Squibb (BMY), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
3/05/2018
Today
3/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:ANTH
Employees
20
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
1.30
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (OTCMKTS:ANTH) was last updated on 3/30/2025 by MarketBeat.com Staff
From Our Partners